Julie Kaiser discusses the findings and implications of a recent study published in PNAS modeling the sequence of events that increases the risk of colonization and infection with multidrug-resistant (MDR) bacteria.
Editor, Martha Powell, discusses the issues around the current guidance for treating HAT and gives an overview of the current clinical pipeline being spearheaded by the Drugs for Neglected Diseases initiative.
In this exclusive piece, the authors look at antihelmintics in both animal and human health – arguing that evolution of resistance necessitates drug development.
Maternal microchimerism (MMc) is a normal part of pregnancy, however, relatively little work has been done exploring the intersection of MMc and infectious disease. Here, Whitney Harrington discusses it’s implications in malaria.
More than a century after its description and the discovery of the bacterial etiological agent, and despite its major burden globally, leptospirosis remains largely under-recognized.
Parechoviruses have been recognized for decades, but the lack of routine diagnostic assays targeting this virus has made it slow for clinical teams to realize the importance of this pathogen as the cause of neonatal and infant sepsis, with possible longer term neurodevelopmental sequelae.
In this report we look at the burden of cryptococcal meningitis, issues with current treatment regimens and future research directions.
In this piece, Fabio Gsaller discusses the mechanisms underpinning antifungal resistance in A. fumigatus and his work on the use of 5-flucytosine as a therapeutic agent in managing aspergillosis.
Several recent papers have investigated how polymicrobial interactions in the cystic fibrosis (CF) lung influence antimicrobial efficacy, demonstrating that microbial metabolites produced by one pathogen can alter the antimicrobial killing of another pathogen.